Browse our comprehensive collection of market intelligence reports.
Following the highlights, this report provides an evidence-based, demand-centric analysis of the U.S. GaAs market. It grounds every analytic statement in government publications or company press releases. The goal is to map how verified technology, policy and corporate actions change immediate demand for GaAs substrates, devices and assemblies across RF, satellite and defense segments.
The market for neural architecture search (NAS) is growing rapidly, as companies are increasingly looking for a faster and more efficient way to design deep learning models. With the demand for optimised neural network models on the rise across all sectors like healthcare, autonomous driving, and edge AI, NAS is quickly establishing itself as a key enabler of next-generation AI development. In addition to its ability to effectively design models faster while improving model performance and co
Piezoelectric devices can convert an acoustic wave into a radio frequency wave or vice versa. Such devices can measure alterations in temperature, force, acceleration, and pressure by converting them into electronic charges. Due to their rich performance benefits, piezoelectric devices are ideal for speakers, energy harvesters, medical devices, navigation equipment, and speakers and microphones.
Radioligand therapy is transforming precision oncology by combining molecular targeting with targeted radioactive payload delivery. Demand for prostate cancer-focused radiopharmaceuticals is increasing because healthcare systems are seeking alternatives to chemotherapy-intensive late-stage oncology management. Isotope production limitations and logistics complexity constrain commercial scalability across global treatment networks. Pharmaceutical companies are expanding isotope manufacturing i
PROTAC-based cancer therapeutics are reshaping oncology drug development through targeted protein degradation mechanisms that eliminate disease-driving proteins instead of inhibiting them. Demand for targeted protein degraders is increasing because resistance to conventional kinase inhibitors and antibody therapies continues limiting long-term oncology outcomes. Clinical validation complexity and intracellular delivery challenges constrain broad commercialization. Pharmaceutical companies are
Imaging diagnostics defines a clinical decision layer where anatomical and molecular visualization is shaping treatment pathways. Demand is expanding as disease burden is rising across oncology and cardiovascular conditions, which is increasing reliance on early-stage detection tools. Cost pressure persists because high capital equipment and maintenance requirements constrain procurement cycles across hospitals. Vendors are responding by shifting toward software-enabled imaging and integrated
Tumor-infiltrating lymphocyte therapy is redefining solid tumor immunotherapy by utilizing a patient’s own tumor-reactive T cells to generate personalized anti-cancer responses. Demand for TIL therapy is increasing because checkpoint inhibitors and targeted therapies continue producing limited outcomes in heavily pretreated patients with refractory solid tumors. Manufacturing complexity and treatment-related toxicity constrain widespread adoption. Cell therapy developers are expanding central
The advanced driver-assistance systems (ADAS) market is driven by electronic technologies that enhance vehicle safety and driving functions. Utilizing sensors, cameras, and radars, ADAS detects obstacles, pedestrians, and blind-spot hazards, significantly reducing accidents and saving lives. Key features include adaptive cruise control, lane departure warnings, and automatic emergency braking, all contributing to improved vehicle safety and road safety.
Transcriptomics in oncology defines molecular-level gene expression profiling that enables cancer characterization, treatment stratification, and therapeutic monitoring. The market exists to translate RNA-level insights into actionable clinical and research outputs, where sequencing platforms, bioinformatics pipelines, and assay standardization are shaping adoption. Demand is shifting from bulk RNA analysis toward single-cell resolution as tumor heterogeneity is becoming a dominant constraint
Proteomics in oncology defines a molecular profiling framework that maps protein expression, interactions, and modifications to understand cancer progression and therapeutic response. The market exists because genomic insights alone fail to capture post-translational dynamics that directly influence tumor behavior. Demand is shifting toward protein-level diagnostics as clinicians are identifying gaps in mutation-only approaches, especially in heterogeneous tumors. Analytical platforms are int
PARP inhibitor therapy defines a targeted oncology segment where DNA damage repair inhibition is enabling tumor-selective cytotoxicity. Clinical adoption is expanding because homologous recombination deficiency is emerging as a scalable biomarker across tumor types. Demand is shifting toward earlier-line usage as clinical evidence is demonstrating survival benefits beyond relapsed settings. Treatment paradigms depend on genomic testing infrastructure, which is constraining access in lower-res
Kinase inhibitor therapy defines a targeted pharmacological approach that blocks aberrant signaling pathways driving disease progression, particularly in oncology and immune-mediated disorders. Demand is shifting toward precision-driven interventions as clinicians are increasingly aligning treatment selection with molecular diagnostics. This shift is tightening dependence on biomarker identification, which limits broad applicability but strengthens therapeutic efficacy in defined patient subs